Brought to you by 
Abbott gets rights to Enanta's HCV protease inhibitors
06 Mar 2020
Executive Summary
Enanta Pharmaceuticals licensed Abbott exclusive worldwide rights to develop and commercialize NS3 and NS3/4A protease inhibitors against hepatitis C virus. Abbott receives IP and US patent rights related to various compounds as well as access to Enanta's drug discovery expertise.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott gets rights to Enanta's HCV protease inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice